Optic complications among hospitalized patients with RA, SLE, and SpA were linked to poor outcomes and higher health care costs, especially among Black and Asian patients.
DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...
Zacks.com on MSN8h
FATE Presents Encourgaing Data From Lupus Study, Stock GainsFate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...
Fate said it is also enrolling a second treatment arm under the Phase 1 Autoimmunity study to evaluate a single dose of FT819 ...
A novel study published in the journal PLOS ONE highlighted the effects of hydroxychloroquine on cardiovascular risk factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback